With Merck patient studies in doubt, 2 analysts downgrade drugmaker’s rating

On Friday, the Whitehouse Station-based company announced it will delay application of a new type of osteoporosis drug to review safety data from one study and look at longer-term data from an extension study

The rest is here:
With Merck patient studies in doubt, 2 analysts downgrade drugmaker’s rating

Leave a Reply